Stratifying into molecular subgroups, we showed a significant favorable prognostic effect of TGIF expression on DFS in ER-positive and HER2-negative tumors and, consequently, in non-TNBC cases in univariate analysis with significant interaction only for HER2-negative BC subgroup. This evidence concerns the gene ESR1 and breast cancer.